Citanest is one of 110 small molecule programs targeting Prostate Carcinoma. It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
84 competitors in Cesarean Section
Fentanyl-Morphine
Ondansetron, Dexamethasone
Acetaminophen/ibuprofen
Sebacoyl Dinalbuphine Ester
Morphine - .
Dynastat
Proamatine
Duragesic
Versed
Catapres
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Regulatory
Jan 1, 1982
CITANEST
NDA NDA014763
Jan 1, 1982
CITANEST PLAIN DENTAL
NDA NDA021382
Sources
Details